Risk Factors for Tumor Lysis Syndrome in Patients With Chronic Lymphocytic Leukemia Treated With the Cyclin-Dependent Kinase Inhibitor, Flavopiridol

Leukemia - United Kingdom
doi 10.1038/leu.2011.109
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Radiation-Induced Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia

Turkish Journal of Haematology
Hematology
2016English

Management of Patients With Chronic Lymphocytic Leukemia Treated With Lenalidomide

Clinical Journal of Oncology Nursing
Oncology
2010English

A Phase I Clinical Trial of FOLFIRI in Combination With the Pan-Cyclin-Dependent Kinase (CDK) Inhibitor Flavopiridol

Cancer Chemotherapy and Pharmacology
Cancer ResearchToxicologyOncologyPharmacology
2010English

DNA Methylation Profiles in Chronic Lymphocytic Leukemia Patients Treated With Chemoimmunotherapy

Clinical Epigenetics
GeneticsDevelopmental BiologyMolecular Biology
2019English

The Cyclin-Dependent Kinase Inhibitor Flavopiridol (Alvocidib) Inhibits Metastasis of Human Osteosarcoma Cells

Oncotarget
Oncology
2018English

Tyrosine Kinase Inhibitor Sequencing in Patients With Chronic Myeloid Leukemia

Oncology and Therapy
Oncology
2019English

Comment on Lipsky Et Al.: Incidence and Risk Factors of Bleeding-Related Adverse Events in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib

Haematologica
Hematology
2016English

Tumour Debulking and Reduction in Predicted Risk of Tumour Lysis Syndrome With Single-Agent Ibrutinib in Patients With Chronic Lymphocytic Leukaemia

British Journal of Haematology
Hematology
2019English

Bruton's Tyrosine Kinase Inhibitor Restrains WNT Signaling in Chronic Lymphocytic Leukemia

Molecular Medicine Reports
OncologyGeneticsMolecular BiologyBiochemistryCancer ResearchMolecular Medicine
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy